Pay in 4 interest-free payments of $6.35 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Unlike earlier-generation weight-management agents, retatrutide is a triple receptor agonist , meaning it simultaneously activates three distinct hormonal receptors: GLP-1 (glucagon-like peptide-1) receptor promotes insulin secretion, reduces appetite, and slows gastric emptying [9] [10] GIP (glucose-dependent insulinotropic polypeptide) receptor enhances insulin release and may improve fat metabolism [12] [13] Glucagon receptor increases energy expenditure and may reduce hepatic steatosis, as suggested by imaging data (MRI-PDFF) from Phase 2 trials, though this effect requires confirmation in larger studies [2] [5] This triple-agonist mechanism distinguishes retatrutide from agents such as semaglutide (GLP-1 only) or tirzepatide (GLP-1/GIP dual agonist), and is thought to produce more pronounced reductions in body weight and improvements in metabolic parameters
California Medicaid was one of the first to cover Wegovy, spending nearly $1 billion before rebates on more than 720,000 prescriptions from 2022 through the end of 2024, according to a Reuters tally of federal data
Jul 7 2020;9(13):e017559
Antioxidant Defense for Nerve Function Alpha Lipoic Acid and Vitamin E reduce oxidative stress, supporting healthy nerve conduction and symptom control in neuropathic conditions
For metformin safety and prescribing details, see the FDA metformin prescribing information
US$ 23.36
US$ 22.05
US$ 24.33
US$ 26.66
US$ 26.57
US$ 20.41
